Why the study?
Does fondaparinux reduce the rate of DVT or PE in patients with superficial vein thrombosis compared to other treatments?
Does fondaparinux reduce the rate of DVT or PE in patients with superficial vein thrombosis compared to other treatments?
Fondaparinux appears to achieve the lowest rate of DVT or PE in patients with superficial vein thrombosis, but definitive conclusions are limited by the low quality of evidence for alternative therapies.
May warrant fondaparinux consideration in superficial vein thrombosis; leaves open confirmation by high-quality trials.
While pooled event rates suggest that fondaparinux achieves the lowest rate of DVT or PE, low-quality evidence for other treatments prevents firm conclusions about the optimal treatment for SVT.
No takes yet. Share an insight, caveat, or question.
Duffett et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: